* Gamma Biologicals Inc., of Houston, reports Genetic Testing Institute Inc., a for-profit company partially owned by the Blood Center Research Foundation, of Milwaukee, has appointed Gamma as the exclusive distributor of FTI enzyme-linked immunosorbent assay (ELISA) testing products in North America and all U.S. territories and protectorates.
* Gelman Sciences, of Ann Arbor, Mich., has introduced its new diagnostic membrane to the lateral flow assay market. The company expects the membrane to significantly displace the use of nitrocellulose membrane in the manufacturing of lateral flow or immunochromatographic assays.
* Instrumentation Laboratory, of Lexington, Mass., reports the addition of ProChrom (Protein C), Factor XI and Factor XII assays to the menu of the ACL Futura random access coagulation analyzer. These new additions allow the use of the IL Test ProChrom chromogenic assay for Protein C determination, as well as the IL Test APTT in conjunction with IL Test Factor Deficient Plasmas for the measurement of Factors XI and XII.
* Mallinckrodt Inc., of St. Louis, and Molecular Biosystems Inc., of San Diego, have filed a marketing authorization application with the European Medicines Evaluation Agency for FS069, Molecular Biosystems' second-generation agent. FS069 is designed to enhance ultrasound imaging by enabling physicians to visualize blood flow and enhance resolution of anatomical structure where ultrasound alone is inadequate.
* Visible Genetics Inc., of Toronto, has signed an agreement with Consolidated Laboratory Services, of Van Nuys, Calif., to develop and carry out early-stage clinical trials on two diagnostic tests for HIV, a quantitative viral load test and a full sequence-based test.